US 11,873,348 B2
Peptides
Peter Ellmark, Lund (SE); Karin Hagerbrand, Hjarup (SE); Laura Varas, Lund (SE); Mattias Levin, Lund (SE); Anna Säll, Lund (SE); and Laura von Schantz, Lund (SE)
Assigned to ALLIGATOR BIOSCIENCE AB, Lund (SE)
Filed by ALLIGATOR BIOSCIENCE AB, Lund (SE)
Filed on Nov. 4, 2022, as Appl. No. 17/980,751.
Claims priority of application No. 2115925 (GB), filed on Nov. 5, 2021; application No. 2204539 (GB), filed on Mar. 30, 2022; and application No. 2212801 (GB), filed on Sep. 2, 2022.
Prior Publication US 2023/0312754 A1, Oct. 5, 2023
Int. Cl. A61K 39/395 (2006.01); A61K 39/00 (2006.01); C07K 16/46 (2006.01); A61P 35/00 (2006.01)
CPC C07K 16/468 (2013.01) [A61P 35/00 (2018.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/77 (2013.01)] 7 Claims
 
1. A method for the treatment of a cancer and/or a tumour in a subject, comprising the step of administering to the subject an effective amount of a bispecific antibody, wherein said bispecific antibody comprises a first binding domain, designated B1, which is capable of binding specifically to CD40, and a second binding domain, designated B2, which is capable of specifically binding to carcinoembryonic antigen (CEA),
wherein binding domain B1 comprises the three CDRs of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 81, 82 and 83; and SEQ ID NO: 96, GNI, and SEQ ID NO: 98); and
wherein binding domain B2 comprises the three CDRs of the heavy chain and the three CDRs of the light chain of antibody ffAC 05337 (SEQ ID NOs: 216, 217 and 239 and SEQ ID NO: 90, AAS, and SEQ ID NO: 311).